Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850253 | 0.96 | HRH3 (0.69) | HRH3KDM4EALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL2842450 | 0.96 | HRH3 (0.69) | HRH3KDM4EALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL2842453 | 0.96 | HRH3 (0.69) | HRH3KDM4EALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL2851722 | 0.78 | HRH3 (0.95) | HRH3KDM4EALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL2841330 | 0.78 | HRH3 (1.00) | HRH3KDM4EALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL2843452 | 0.77 | HRH3 (0.49) | HRH3CYP2D6CYP2C19 | |
| SCHEMBL2843455 | 0.77 | HRH3 (0.49) | HRH3CYP2D6CYP2C19 | |
| SCHEMBL2845346 | 0.77 | HRH3 (0.49) | HRH3CYP2D6CYP2C19 | |
| SCHEMBL13300110 | 0.76 | HRH3 (0.50) | HRH3ALDH1A1CYP2D6CYP2C19TSHR | |
| SCHEMBL13299806 | 0.76 | HRH3 (0.50) | HRH3ALDH1A1CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885KDM4E 1779/4885ALDH1A1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.